A multicentre prospective single-arm clinical trial to evaluate the treatment outcomes of prophylactic laparoscopic lateral pelvic lymph node dissection for advanced lower rectal cancer
- PMID: 40166886
- PMCID: PMC11959524
- DOI: 10.1111/codi.70078
A multicentre prospective single-arm clinical trial to evaluate the treatment outcomes of prophylactic laparoscopic lateral pelvic lymph node dissection for advanced lower rectal cancer
Abstract
Aim: There has been no prospective multicentre validation of the treatment outcomes of minimally invasive lateral pelvic lymph node dissection for lower rectal cancer; hence, this prospective study aimed to evaluate the treatment outcomes of prophylactic laparoscopic lateral pelvic lymph node dissection.
Method: Between May 2018 and August 2021, 90 patients with Stage II-III rectal cancer were registered. The clearance range for lateral pelvic lymph node dissection included the lymph nodes around the internal iliac artery and the obturator lymph nodes, while the autonomic nerves were generally preserved. The primary outcome was the incidence of Grade III-IV postoperative complications at discharge. The secondary outcomes were surgical and pathological outcomes, urinary function, sexual function, disease-free survival and overall survival. The experience of each facility and surgeon requirements were set to maintain quality control of lateral pelvic lymph node dissection.
Results: Of the 90 patients, 87 were analysed after exclusion of ineligible patients. There were 30 and 57 cases, respectively, of Stage II and III rectal cancer, among which 17 patients underwent neoadjuvant chemotherapy. The median operating time and blood loss were 472 min and 55 mL, respectively. Postoperative complications were observed in 22 patients (25.3%), and the primary outcome of Grade III postoperative complication was observed in five patients (5.7%). Eight lateral lymph nodes were harvested bilaterally, and lateral lymph node metastasis was observed in 14 patients.
Conclusion: Prophylactic lateral pelvic lymph node dissection can be safely performed with adequately quality-controlled laparoscopic procedures.
Keywords: laparoscopic surgery; lateral pelvic lymph node dissection; rectal cancer; short‐term outcomes.
© 2025 The Author(s). Colorectal Disease published by John Wiley & Sons Ltd on behalf of Association of Coloproctology of Great Britain and Ireland.
Conflict of interest statement
The authors declare no conflict of interests for this article.
Figures
References
-
- Bahadoer RR, Dijkstra EA, van Etten B, Marijnen CAM, Putter H, Kranenbarg EM, et al. Short‐course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open‐label, phase 3 trial. Lancet Oncol. 2021;22:29–42. 10.1016/S1470-2045(20)30555-6 - DOI - PubMed
-
- Conroy T, Bosset JF, Etienne PL, Rio E, François É, Mesgouez‐Nebout N, et al. Neoadjuvant chemotherapy with folfirinox and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER‐PRODIGE 23): a multicentre, randomised, open‐label, phase 3 trial. Lancet Oncol. 2021;22:702–715. 10.1016/S1470-2045(21)00079-6 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
